Herein, we demonstrate that AAV encoding for the lymphotactic chemokine CXCL9 can be leveraged to engage the immune system to recognize and attack tumor cells by modulating anti-PD-1 immunotherapy in the combinatorial setting. This evidence concerns the gene CXCL9 and neoplasm.